Head & neck · 2026
Survival Outcomes of Head and Neck Neuroendocrine Carcinoma: A Systematic Review.
СтатьяСистематический обзорОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aïta Morena, Galofaro Ilario, Maniaci Antonino, Lechien Jerome R
Аннотация
BACKGROUND: This systematic review investigated pathological, oncological, and survival outcomes of Head and neck neuroendocrine carcinoma (HNNEC).
METHODS: Three independent investigators conducted a PRISMA-compliant literature search. Primary outcomes included tumor stage, overall survival (OS), disease-free survival, recurrence, metastasis, and therapeutic strategies.
RESULTS: The most common locations were the larynx (n = 1041), sinonasal tract (n = 917), and oropharynx (n = 366), mostly cT2/cT4 and cN0/cN2. Small-cell carcinoma predominated (n = 2334). Laryngeal tumors were preferentially treated by surgery plus radiotherapy, sinonasal/nasopharyngeal tumors by chemoradiotherapy, and salivary tumors by surgery with adjuvant therapy. Surgical cohorts achieved 5-year OS of 33.0%-73.9%, and multimodal CRT-plus-surgery 57.2%-61.0%. Laryngeal and mucosal tumors had more favorable outcomes than sinonasal/salivary localizations; well/moderately-differentiated carcinoids outperformed poorly-differentiated and small-cell variants (median OS < 24 months).
CONCLUSION: HNNEC survival strongly depends on histology, site, and treatment modality. Substantial therapeutic heterogeneity reflects the lack of guidelines, highlighting the need for standardized, histology- and site-specific management recommendations.
METHODS: Three independent investigators conducted a PRISMA-compliant literature search. Primary outcomes included tumor stage, overall survival (OS), disease-free survival, recurrence, metastasis, and therapeutic strategies.
RESULTS: The most common locations were the larynx (n = 1041), sinonasal tract (n = 917), and oropharynx (n = 366), mostly cT2/cT4 and cN0/cN2. Small-cell carcinoma predominated (n = 2334). Laryngeal tumors were preferentially treated by surgery plus radiotherapy, sinonasal/nasopharyngeal tumors by chemoradiotherapy, and salivary tumors by surgery with adjuvant therapy. Surgical cohorts achieved 5-year OS of 33.0%-73.9%, and multimodal CRT-plus-surgery 57.2%-61.0%. Laryngeal and mucosal tumors had more favorable outcomes than sinonasal/salivary localizations; well/moderately-differentiated carcinoids outperformed poorly-differentiated and small-cell variants (median OS < 24 months).
CONCLUSION: HNNEC survival strongly depends on histology, site, and treatment modality. Substantial therapeutic heterogeneity reflects the lack of guidelines, highlighting the need for standardized, histology- and site-specific management recommendations.